Natco Pharma

Natco Pharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Natco Pharma (NATCOPHARM.NS) as of Oct 23, 2026 is 97.09 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 68.72 % — a change of 41.28% (higher).

FCF Conversion

97.09 %

YoY

41.28%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Natco Pharma is 2026 97.09 % . FCF Conversion Rate (FCF/EBITDA) of Natco Pharma was 2025 68.72 % . It decreases by 41.28% higher compared to the previous year.

The Natco Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
32.14 INR
Jan 1, 2020
12.74 INR
Jan 1, 2021
10.02 INR
Jan 1, 2022
-115.41 INR
Jan 1, 2023
89.96 INR
Jan 1, 2024
64.37 INR
Jan 1, 2025
68.72 INR
Jan 1, 2026
97.09 INR
The Natco Pharma FCF Conversion history
YEARFCF ConversionYoY
97.09 %+41.28%
68.72 %+6.77%
64.37 %-28.45%
89.96 %-177.95%
-115.41 %-1,251.25%
10.02 %-21.30%
12.74 %-60.36%
32.14 %+469.33%
5.64 %-58.62%
13.64 %-138.97%
-35.00 %+77.52%
-19.72 %-160.17%
32.77 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Natco Pharma Stock analysis

What does Natco Pharma do? Natco Pharma Ltd is an Indian pharmaceutical company that was founded in 1981. It is headquartered in Hyderabad, India and also operates branches in other parts of India and overseas. History Natco Pharma Ltd was founded by Dr. Devinder Pal Singh. The company started as a small generic drug manufacturing company but gradually expanded and today is one of the leading pharmaceutical companies in India. In the early 2000s, Natco Pharma Ltd entered the international market and has since conducted many important partnerships and acquisitions to expand its business. Business model Natco Pharma Ltd's business model focuses on the research, development, and manufacturing of drugs used in various therapeutic areas. The company primarily produces generics but also biosimilars and innovative products. Natco Pharma Ltd aims to provide affordable and accessible medications to patients in India and worldwide. Products and divisions Natco Pharma Ltd produces a wide range of medications divided into various divisions. The company's main divisions include oncology, hepatitis C, nephrology, neurology, cardiology, and anti-infectives. Natco Pharma Ltd also offers a range of biosimilars, including pegfilgrastim and trastuzumab, and has launched innovative products such as Natdac (daclatasvir) and Hepcinat LP (sofosbuvir and ledipasvir). The company also has a separate department for the production of active pharmaceutical ingredients (APIs) and has multiple manufacturing facilities in different parts of India certified by strict international quality standards (such as USFDA, UK-MHRA, and TGA). Activities Natco Pharma Ltd has been involved in several patent litigation cases to facilitate access to affordable generic medications. A significant example is the patented cancer drug Nexavar by Bayer. Natco Pharma Ltd won a long legal battle, allowing it to bring a cheaper version of the drug to the market. Natco Pharma Ltd has also built partnerships with other pharmaceutical companies to promote the distribution of its medications on a global level. One important collaboration of the company is with Mylan to manufacture affordable versions of HIV/AIDS medications for developing countries. Conclusion Natco Pharma Ltd is a strong example of a company that has been able to grow through quality, research, and affordable products. It has also been involved in several patent disputes to improve access to affordable medications. The wide range of medications and divisions shows that Natco Pharma Ltd is a significant player in the Indian and international market. Natco Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Natco Pharma stock

FCF Conversion Rate (FCF/EBITDA) of Natco Pharma is 97.09 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Natco Pharma changed from 68.72 % to 97.09 %, representing a 41.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Natco Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Natco Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Natco Pharma

All Key Metrics — Natco Pharma